PE20170146A1 - Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carboxamida - Google Patents
Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carboxamidaInfo
- Publication number
- PE20170146A1 PE20170146A1 PE2016002765A PE2016002765A PE20170146A1 PE 20170146 A1 PE20170146 A1 PE 20170146A1 PE 2016002765 A PE2016002765 A PE 2016002765A PE 2016002765 A PE2016002765 A PE 2016002765A PE 20170146 A1 PE20170146 A1 PE 20170146A1
- Authority
- PE
- Peru
- Prior art keywords
- acetylpiperidin
- dihydroisoquinolin
- carboxamide
- pyrimidine
- hydroxypropyl
- Prior art date
Links
- -1 AMINO Chemical class 0.000 title 1
- HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 title 1
- JLCCNYVTIWRPIZ-NRFANRHFSA-N 6-[(1-acetylpiperidin-4-yl)amino]-n-[(2s)-3-(3,4-dihydro-1h-isoquinolin-2-yl)-2-hydroxypropyl]pyrimidine-4-carboxamide Chemical compound C1CN(C(=O)C)CCC1NC1=CC(C(=O)NC[C@H](O)CN2CC3=CC=CC=C3CC2)=NC=N1 JLCCNYVTIWRPIZ-NRFANRHFSA-N 0.000 abstract 2
- 101000924530 Homo sapiens Protein arginine N-methyltransferase 5 Proteins 0.000 abstract 2
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 150000003890 succinate salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462016819P | 2014-06-25 | 2014-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170146A1 true PE20170146A1 (es) | 2017-03-08 |
Family
ID=53510948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016002765A PE20170146A1 (es) | 2014-06-25 | 2015-06-23 | Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carboxamida |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US9884846B2 (enExample) |
| EP (1) | EP3160958B1 (enExample) |
| JP (1) | JP6559719B2 (enExample) |
| KR (1) | KR102493854B1 (enExample) |
| CN (1) | CN106536511B (enExample) |
| AU (1) | AU2015278728B2 (enExample) |
| BR (1) | BR112016030586B1 (enExample) |
| CA (1) | CA2952567A1 (enExample) |
| CL (1) | CL2016003278A1 (enExample) |
| CR (1) | CR20160598A (enExample) |
| CY (1) | CY1124085T1 (enExample) |
| DK (1) | DK3160958T3 (enExample) |
| DO (1) | DOP2016000333A (enExample) |
| EA (1) | EA032017B1 (enExample) |
| ES (1) | ES2869374T3 (enExample) |
| HR (1) | HRP20210681T1 (enExample) |
| HU (1) | HUE054454T2 (enExample) |
| IL (1) | IL249491A0 (enExample) |
| LT (1) | LT3160958T (enExample) |
| MA (1) | MA40219B1 (enExample) |
| MX (1) | MX2017000134A (enExample) |
| PE (1) | PE20170146A1 (enExample) |
| PH (1) | PH12016502523A1 (enExample) |
| PL (1) | PL3160958T3 (enExample) |
| PT (1) | PT3160958T (enExample) |
| RS (1) | RS61731B1 (enExample) |
| SG (1) | SG11201610709UA (enExample) |
| SI (1) | SI3160958T1 (enExample) |
| SM (1) | SMT202100260T1 (enExample) |
| WO (1) | WO2015198229A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY199894A (en) | 2012-12-21 | 2023-11-27 | Epizyme Inc | Prmt5 inhibitors and uses thereof |
| CA2953572A1 (en) * | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| GB201604030D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604022D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604027D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604031D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604020D0 (en) * | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604029D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| US11098059B2 (en) | 2017-11-08 | 2021-08-24 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| UA126349C2 (uk) | 2017-12-13 | 2022-09-21 | Люпін Лімітед | Заміщені біциклічні гетероциклічні сполуки як інгібітори prmt5 |
| US12391695B2 (en) | 2019-06-10 | 2025-08-19 | Lupin Limited | PRMT5 inhibitors |
| KR20220086628A (ko) | 2019-10-22 | 2022-06-23 | 루핀 리미티드 | Prmt5 저해제의 약학적 조합물 |
| WO2021111322A1 (en) | 2019-12-03 | 2021-06-10 | Lupin Limited | Substituted nucleoside analogs as prmt5 inhibitors |
| CN112206218B (zh) * | 2020-10-24 | 2022-08-23 | 迪沙药业集团有限公司 | 一种甲硝唑维生素b6组合物 |
| AU2023327684A1 (en) | 2022-08-15 | 2025-03-20 | Astrazeneca Ab | Mta-cooperative prmt5 inhibitors for use in the treatment of cancer |
| KR102851417B1 (ko) * | 2022-08-16 | 2025-08-28 | 제이투에이치바이오텍 (주) | 피리미딘-4-카복사마이드 화합물의 결정형 및 이를 포함하는 경구용 약학 제제 |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| FR2634376B1 (fr) | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
| IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
| IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| EP0644755B1 (en) | 1992-06-10 | 1997-03-19 | NanoSystems L.L.C. | Surface modified nsaid nanoparticles |
| NZ248813A (en) | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
| US5298262A (en) | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
| US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US5302401A (en) | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5340564A (en) | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
| US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
| US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
| US5587143A (en) | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
| US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
| US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5569448A (en) | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5560931A (en) | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5571536A (en) | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5503723A (en) | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
| US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5518738A (en) | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
| US5622938A (en) | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
| US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
| US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
| US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
| US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
| WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
| US9044432B2 (en) * | 2009-12-22 | 2015-06-02 | Ohio State Innovation Foundation | Compositions and methods for cancer detection and treatment |
| CN102199623A (zh) * | 2011-03-22 | 2011-09-28 | 中国科学院遗传与发育生物学研究所 | 蛋白质精氨酸甲基转移酶5的新用途 |
| MY199894A (en) | 2012-12-21 | 2023-11-27 | Epizyme Inc | Prmt5 inhibitors and uses thereof |
-
2015
- 2015-06-23 JP JP2016575040A patent/JP6559719B2/ja not_active Expired - Fee Related
- 2015-06-23 CN CN201580040248.3A patent/CN106536511B/zh not_active Expired - Fee Related
- 2015-06-23 HU HUE15733921A patent/HUE054454T2/hu unknown
- 2015-06-23 HR HRP20210681TT patent/HRP20210681T1/hr unknown
- 2015-06-23 MA MA40219A patent/MA40219B1/fr unknown
- 2015-06-23 BR BR112016030586-8A patent/BR112016030586B1/pt not_active IP Right Cessation
- 2015-06-23 CA CA2952567A patent/CA2952567A1/en not_active Abandoned
- 2015-06-23 WO PCT/IB2015/054712 patent/WO2015198229A1/en not_active Ceased
- 2015-06-23 PL PL15733921T patent/PL3160958T3/pl unknown
- 2015-06-23 PE PE2016002765A patent/PE20170146A1/es not_active Application Discontinuation
- 2015-06-23 ES ES15733921T patent/ES2869374T3/es active Active
- 2015-06-23 SM SM20210260T patent/SMT202100260T1/it unknown
- 2015-06-23 PT PT157339219T patent/PT3160958T/pt unknown
- 2015-06-23 KR KR1020177001796A patent/KR102493854B1/ko active Active
- 2015-06-23 MX MX2017000134A patent/MX2017000134A/es unknown
- 2015-06-23 SG SG11201610709UA patent/SG11201610709UA/en unknown
- 2015-06-23 CR CR20160598A patent/CR20160598A/es unknown
- 2015-06-23 US US15/318,714 patent/US9884846B2/en active Active
- 2015-06-23 AU AU2015278728A patent/AU2015278728B2/en not_active Ceased
- 2015-06-23 SI SI201531556T patent/SI3160958T1/sl unknown
- 2015-06-23 DK DK15733921.9T patent/DK3160958T3/da active
- 2015-06-23 RS RS20210484A patent/RS61731B1/sr unknown
- 2015-06-23 EA EA201692465A patent/EA032017B1/ru not_active IP Right Cessation
- 2015-06-23 LT LTEP15733921.9T patent/LT3160958T/lt unknown
- 2015-06-23 EP EP15733921.9A patent/EP3160958B1/en active Active
-
2016
- 2016-12-11 IL IL249491A patent/IL249491A0/en unknown
- 2016-12-16 PH PH12016502523A patent/PH12016502523A1/en unknown
- 2016-12-21 CL CL2016003278A patent/CL2016003278A1/es unknown
- 2016-12-22 DO DO2016000333A patent/DOP2016000333A/es unknown
-
2017
- 2017-12-13 US US15/840,086 patent/US9981948B2/en active Active
-
2021
- 2021-04-29 CY CY20211100373T patent/CY1124085T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170146A1 (es) | Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carboxamida | |
| SG11202012656WA (en) | Heterocyclic compounds useful in the treatment of disease | |
| CR20140378A (es) | Derivados de pirido[2,3-d] pirimidina sustituidos con 2-amino, 6-fenilo útiles como inhibidores de cinasa raf | |
| CY1119199T1 (el) | Αναστολεις cdc7 | |
| BR112012027743A2 (pt) | ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas | |
| MX374729B (es) | Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4. | |
| NI201800042A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1 | |
| MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
| MY175450A (en) | 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides | |
| PH12018500284B1 (en) | 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer | |
| MX2016006432A (es) | Tetrahidro-benzodiazepinonas. | |
| IL250021B (en) | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors | |
| EA201791066A1 (ru) | Твердые формы ингибитора ask1 | |
| CL2015002628A1 (es) | Compuestos de heteroarilo y sus usos. | |
| CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
| CL2015003444A1 (es) | Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo | |
| SG10201805628TA (en) | Deuterated heterocyclic compounds and their use as imaging agents | |
| CO2017004784A2 (es) | Isómeros de ácido-1-[(3-cloro-2-fluoro-fenil)metil]-4-[[3-fluoro-6-[(5-metil-1h-pirazol-3-il)amino]-2-piridil]metil]-2-metil-piperidin-4-carboxílico como inhibidores de la cinasa aurora a | |
| CL2015002701A1 (es) | Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (s)-quinuclidin-3-ilo | |
| EA201591649A1 (ru) | Составы с органическими соединениями | |
| EA201790275A1 (ru) | Кристаллические формы 6-((6,7-диметоксихиназолин-4-ил)окси)-n,2-диметилбензофуран-3-карбоксамида | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| ZA201802399B (en) | Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer | |
| IN2013CH04330A (enExample) | ||
| TH168688A (th) | เกลือที่เป็นผลึกของ (s)-6-((1-อะซิทิลพิเพอริดิน-4-อิล)อะมิโน)-n-(3-(3,4-ไดไฮโดรไอโซควิโนลิน-2(1h)-อิล)-ไฮดรอกซีโพรพิล)ไพริมิดีน-4-คาร์บอกซาไมด์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |